Surrozen, Inc. (SRZN) Bundle
An Overview of Surrozen, Inc. (SRZN)
General Summary of Surrozen, Inc. (SRZN)
Surrozen, Inc. is a biotechnology company focused on developing regenerative medicines for gastrointestinal and liver diseases. The company was founded in 2015 and is headquartered in South San Francisco, California.
Company Products and Services
Surrozen specializes in developing therapeutics targeting the Wnt pathway for tissue regeneration. Key product candidates include:
- SZN-413: Liver regeneration therapeutic
- SZN-1326: Gastrointestinal disease treatment
Financial Performance in Latest Reporting Period
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $12.4 million |
| Research & Development Expenses | $35.6 million |
| Net Loss | $41.2 million |
| Cash and Cash Equivalents | $87.5 million |
Industry Leadership
Surrozen demonstrates leadership in regenerative medicine through its innovative Wnt pathway approach and robust clinical pipeline.
- Unique therapeutic platform targeting tissue regeneration
- Multiple clinical-stage programs in liver and gastrointestinal diseases
- Backed by significant venture capital investments
Key Company Statistics
| Metric | 2024 Data |
|---|---|
| Employees | 78 |
| Current Stock Price | $3.45 |
| Market Capitalization | $124 million |
Mission Statement of Surrozen, Inc. (SRZN)
Mission Statement of Surrozen, Inc. (SRZN)
Surrozen, Inc. mission statement focuses on regenerative medicine and tissue repair technologies targeting specific medical conditions.
Core Mission Components
| Research Focus | Wnt pathway regenerative therapeutics |
| Primary Disease Target | Liver, gastrointestinal, and retinal disorders |
| Clinical Stage | Preclinical and Phase 1/2 development |
Key Research Objectives
- Develop novel regenerative therapies using Wnt pathway modulation
- Target unmet medical needs in tissue repair
- Advance therapeutic approaches for chronic diseases
Scientific Approach
Surrozen's mission is executed through proprietary Wnt pathway agonist technologies.
| Patent Portfolio | 7 issued patents as of 2024 |
| R&D Investment | $12.4 million in 2023 |
| Research Personnel | 23 specialized scientists |
Therapeutic Development Pipeline
- SZN-413: Liver regeneration program
- SZN-FAP: Fibrosis therapeutic candidate
- Retinal disease regeneration platform
Nasdaq listing: SRZN, with market capitalization of approximately $87.6 million as of January 2024.
Vision Statement of Surrozen, Inc. (SRZN)
Vision Statement of Surrozen, Inc. (SRZN) in 2024
Regenerative Medicine FocusSurrozen, Inc. targets Wnt pathway-based regenerative therapeutics for chronic diseases. As of Q4 2023, the company concentrates on developing treatments for liver, gastrointestinal, and metabolic disorders.
| Research Area | Current Development Stage | Target Indication |
|---|---|---|
| Liver Regeneration | Preclinical | Non-alcoholic Steatohepatitis (NASH) |
| Gastrointestinal Repair | Phase 1 | Inflammatory Bowel Disease |
Surrozen's vision emphasizes proprietary Wnt pathway modulation technologies. The company has 14 active patent applications as of January 2024.
- Total R&D Investment: $22.3 million in 2023
- Research Personnel: 37 specialized scientists
- Pipeline Therapeutic Candidates: 3 primary programs
| Program | Therapeutic Area | Estimated Clinical Advancement |
|---|---|---|
| SZN-1326 | Liver Regeneration | Phase 2 by Q3 2024 |
| SZN-2345 | Gastrointestinal Repair | Phase 1b by Q4 2024 |
Surrozen maintains strategic partnerships with 4 academic research institutions and 2 pharmaceutical companies in 2024.
Core Values of Surrozen, Inc. (SRZN)
Core Values of Surrozen, Inc. (SRZN) in 2024
Scientific Innovation and Research ExcellenceAs of Q1 2024, Surrozen, Inc. demonstrates commitment to scientific innovation through focused research in regenerative medicine and tissue repair.
| R&D Investment | Research Focus Areas | Patent Applications |
|---|---|---|
| $18.3 million | Wnt pathway therapeutics | 7 new applications in 2024 |
- Liver regeneration programs
- Gastrointestinal tissue repair technologies
- Stem cell modulation research
Surrozen maintains 3 active research partnerships with academic institutions in 2024.
| Partner Institution | Collaboration Focus | Duration |
|---|---|---|
| Stanford University | Liver regeneration | 2022-2025 |
| UCSF | Stem cell research | 2023-2026 |
Surrozen adheres to strict ethical research guidelines with 100% compliance to NIH and FDA regulatory standards.
- Zero ethical violations reported in 2023-2024
- Full transparency in clinical trial reporting
- Independent ethics review board oversight
Clinical pipeline focuses on unmet medical needs with 2 lead therapeutic candidates in advanced stages.
| Therapeutic Candidate | Disease Target | Clinical Stage |
|---|---|---|
| SZN-413 | Liver fibrosis | Phase 2 |
| SZN-522 | Intestinal disorders | Phase 1/2 |
Surrozen, Inc. (SRZN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.